Why the study?
Does pimobendan improve exercise tolerance and quality of life in ambulatory patients with moderate to severe heart failure?
Population
198 ambulatory patients with symptoms of moderate to severe heart failure despite therapy with digitalis and…
Comparison
Pimobendan 2.5 mg/day, 5 mg/day, or 10 mg/day… vs Placebo for 12 weeks.
Design
RCT, randomly assigned, double-blind
Follow-up
12 weeks
Authors
Loading...
Supports pimobendan 5 mg to enhance exercise tolerance in moderate-severe HF; confirms functional benefits from inodilators in ambulatory patients.
Does pimobendan improve exercise tolerance and quality of life in ambulatory patients with moderate to severe heart failure?
Pimobendan 5 mg/day significantly improves exercise duration, peak VO2, and quality of life in patients with moderate to severe heart failure.
Kubo et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: